Stockscreener 앱 받기
2.86
1.38%
-0.04
시간 외 거래:
2.70
-0.16
-5.59%
전일 마감가:
$2.90
열려 있는:
$2.91
하루 거래량:
370.49K
Relative Volume:
1.45
시가총액:
$284.36M
수익:
$4.60M
순이익/손실:
$-82.31M
주가수익비율:
-3.487
EPS:
-0.8202
순현금흐름:
$-87.79M
1주 성능:
+13.04%
1개월 성능:
+28.25%
6개월 성능:
+5.15%
1년 성능:
+33.02%
1일 변동 폭
$2.7986
$3.00
1주일 범위
$2.435
$3.00
52주 변동 폭
$2.03
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.86 | 262.49M | 4.60M | -82.31M | -87.79M | -0.8202 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-31 | 개시 | BTIG Research | Buy |
| 2019-02-01 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-01-04 | 개시 | UBS | Buy |
| 2018-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-03-23 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | 개시 | Credit Suisse | Outperform |
| 2016-10-18 | 개시 | Jefferies | Buy |
| 2016-10-18 | 개시 | Leerink Partners | Outperform |
모두보기
Ac Immune Sa 주식(ACIU)의 최신 뉴스
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Positive Ph1 results for AC Immune's NLRP3 inflammasome inhibitor - pharmaphorum
AC (ACIU) Financial Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Market Price Moves 2.33% Higher on the DayConsensus Forecast Report - vinanet.vn
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline - Benzinga
ACIU Reiterated by BTIG -- Price Target Maintained at $8.00 - GuruFocus
AC Immune's NLRP3 inhibitor reaches brain with safety intact in first human study - AllSci
AC Immune shares rise after encouraging early Phase 1 data for ACI-19764 - Yahoo Finance
AC Immune stock gains on early Phase 1 trial results By Investing.com - Investing.com Australia
AC Immune stock gains on early Phase 1 trial results - Investing.com
AC Immune posts trial data for inflammatory drug (ACIU:NASDAQ) - Seeking Alpha
AC Immune reports phase 1 safety data for NLRP3 inhibitor By Investing.com - Investing.com Nigeria
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764 - TipRanks
AC Immune (NASDAQ: ACIU) advances NLRP3 pill into heart-risk trial - Stock Titan
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 - GlobeNewswire
AC Immune takes Parkinson's vaccine into US trials as Phase II data near - AllSci
ACIU Q2 2026 Earnings: Surprise EPS Beat of 117.61% Offers Little Support as Shares Slip 1.91%Quarterly Financial Update - vinanet.vn
ACIU Looks 33.6% Undervalued on GF Value™ Despite Financial Chal - GuruFocus
AC Immune receives FDA fast track status for parkinson’s drug By Investing.com - Investing.com Nigeria
AC Immune Wins FDA Fast Track for ACI-7104 in Early Parkinson’s Disease - TipRanks
AC Immune receives FDA fast track status for parkinson’s drug - Investing.com
AC Immune (NASDAQ: ACIU) gains FDA Fast Track, IND clearance for Parkinson’s drug ACI-7104 - Stock Titan
AC Immune’s Parkinson’s Candidate Shows 100% Responder Rate - Stock Titan
AC Immune SA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - simplywall.st
Analyst Reiterates Buy on AC Immune as 2H26 Catalysts Approach; Price Target Maintained at $12 - tipranks.com
AC Immune (NasdaqGM:ACIU) Stock Price Shrugs Off Surprise Quarterly Profit - Sahm
ACIU Reiterated by BTIG -- Maintains Price Target at $8.00 - GuruFocus
AC Immune SA reports results for the quarter ended June 30Earnings Summary - TradingView
AC Immune Files First-Half 2026 Results and Corporate Update on Form 6-K - tipranks.com
AC Immune: Q2 Earnings Snapshot - Barchart.com
AC Immune First Half 2026 Financial and Corporate Update - The Manila Times
Partner milestones lift AC Immune (NASDAQ: ACIU) cash and cut loss - stocktitan.net
AC Immune’s Parkinson’s Trial Gets a $4 Million Grant - Stock Titan
ACIU Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesAnalyst Drop Coverage - vinanet.vn
AC Immune (ACIU) Drops 6.12% as Support at $2.12 Comes into FocusBuy Signal Reports - Vinanet
ACIU Q2'26 Earnings: EPS estimate is 0.12 USD - TradingView
AC Immune SA (ACIU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AC Immune SA (ACIU) Institutional Confidence - TradingKey
AC Immune SA (ACIU) Cash Flow - TradingKey
TradingKey - TradingKey
AC Immune SA (ACIU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ACIU|AC Immune SA|Price:2.230|Chg%:-0.010 - TradingKey
AC Immune SA Revenue Breakdown – TRADEGATE:IMR - TradingView
ACIU Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineEBITDA Margin Trends - vinanet.vn
AC Immune SA (ACIU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ACIU Q2'26 Earnings: revenue estimate is 34.08M USD - TradingView
AC Immune Q1 2026 Earnings: Narrower Loss and Positive Surprise Highlight ProgressProduct Revenue Analysis - dars.gov.et
AC Immune (ACIU) Posts Modest Gain, Holds Above Key SupportDay Trade Opportunities - dars.gov.et
AC Immune SA (ACIU) Holds Near Support After Marginal DeclineMA Crossover - dars.gov.et
AC Immune Q1 2026 Earnings: Narrowed Loss Per Share Exceeds Expectations, Stock RisesAnalyst Coverage Count - dars.gov.et
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 - The Manila Times
AC Immune brings three neurodegeneration studies to AAIC 2026 - Stock Titan
Ac Immune Sa (ACIU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):